Preferred Label : Tyrosine Kinase Inhibitor XL228;
NCIt related terms : XL-228;
NCIt definition : A synthetic molecule that targets multiple tyrosine kinases with potential antineoplastic
activity. Tyrosine kinase inhibitor XL228 binds to and inhibits the activities of
multiple tyrosine kinases, such as the insulin-like growth factor 1 receptor (IGF1R),
Src tyrosine kinase, and Bcr-Abl tyrosine kinase. Blockade of these kinases may result
in the inhibition of tumor angiogenesis, cell proliferation, and metastasis. In addition,
this agent may be a potent inhibitor of the T315I mutant form of the Abl protein,
which is associated with the resistance of chronic myelogenous leukemia (CML) to other
tyrosine kinase inhibitors. IGF1R and Src tyrosine kinases are upregulated in many
tumor cells and play important roles in tumor cell proliferation and metastasis. Bcr-Abl
translocation leads to constitutive activation of ABL kinase and is commonly associated
with Philadelphia-positive acute lymphocytic leukemia (ALL).;
UNII : 33M2XSK003;
CAS number : 898280-07-4;
Molecule name : XL228;
NCI Metathesaurus CUI : CL374367;
Origin ID : C68929;
UMLS CUI : C2348842;
Semantic type(s)
- concept_is_in_subset
- has_target
